Pembrolizumab (Keytruda)
Canadian Journal of Health Technologies · 16.11.2026 · 6 (11)
DOI: 10.51731/cjht.2026.1568 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 16.11.2026. Verfasst von CDA-AMC.
Abstract (Originalsprache)
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Pembrolizumab (Keytruda), 100 mg per 4 mL vial, solution for IV infusion. Indication: Pembrolizumab, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with MIBC who are ineligible for cisplatin-containing chemotherapy.
Zitieren
APA
CDA-AMC (2026). Pembrolizumab (Keytruda). Canadian Journal of Health Technologies, 6(11). https://doi.org/10.51731/cjht.2026.1568
Vancouver
CDA-AMC. Pembrolizumab (Keytruda). Canadian Journal of Health Technologies. 2026;6(11). doi:10.51731/cjht.2026.1568
BibTeX
@article{CDAAMC2026,
author = {CDA-AMC},
title = {Pembrolizumab (Keytruda)},
journal = {Canadian Journal of Health Technologies},
year = {2026},
volume = {6},
number = {11},
doi = {10.51731/cjht.2026.1568}
}
EUVIMED